Personalized chemotherapy and immunotherapy for high PD-L1 lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new way of giving chemotherapy and an immunotherapy drug (cemiplimab) before surgery for lung cancer that has a high PD-L1 level. The goal is to see if a shorter or adjusted course can shrink the tumor and improve outcomes while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years of age or older.
- Your lung cancer must be stage II to IIIB (N2), and it must be possible to remove it with surgery.
- Your tumor must have a high level of PD-L1 (at least 50%) – a protein that helps cancer hide from the immune system.
- You must be in generally good health (able to walk and take care of yourself), and your lungs must be strong enough for surgery.
- You must not have certain gene changes (like EGFR or ALK) in your tumor, and you must not have cancer that has spread to the brain.
- You must not have had prior treatment with an immunotherapy drug (like PD-1 or PD-L1 inhibitors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
This trial is testing a combination of treatments (an immunotherapy drug called cemiplimab plus chemotherapy) for people with advanced lung cancer that has not been treated yet and shows a high PD-L1 level. The study also looks at a specific blood marker to see if it predicts how the cancer responds, aiming to avoid rapid growth (hyperprogression).
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
This trial tests a drug called cemiplimab, which helps your immune system fight cancer. It is given before and after surgery to try to reduce the chance of the cancer coming back.
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
This trial tests giving just three cycles of immunotherapy (cemiplimab) without surgery or radiation, specifically for people with early-stage (stage IA) non-small cell lung cancer who cannot have surgery. It aims to see if this shorter treatment can control the cancer with fewer side effects.
Hear when a new NSCLC Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.